Cancer Research  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 50, 1231-1236, February 15, 1990]
© 1990 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jeannesson, P.
Right arrow Articles by Tökés, Z. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jeannesson, P.
Right arrow Articles by Tökés, Z. A.

Induction of Erythroid Differentiation in Human Leukemic K-562 Cells by Membrane-directed Action of Adriamycin Covalently Bound to Microspheres1

Pierre Jeannesson2, Chantal Trentesaux, Brigitte Gèrard, Jean-Claude Jardillier, Kevin L. Ross and Zoltán A. Tökés

Institut Jean Godinot, 1 rue du Gènèral Koenig, 51100 Reims, France [P. J., C. T., B. G., J-C. J.], and Department of Biochemistry, Biochemistry, Kenneth Norris, Jr., Comprehensive Cancer, University of Southern California, School of Medicine, Los Angeles, California 90033 [K. L. R., Z. A. T.]

Covalent coupling of Adriamycin (ADR) to polyglutaraldehyde microspheres focuses the drug action to the plasma membrane which leads to growth inhibition and also to induction of erythroid differentiation in human leukemic K-562 cells without any evidence of cellular internalization of the drug-microsphere complexes. As observed with the free drug, a reduction in cell growth by the coupled drug correlated with a recruitment of differentiating cells. Treatment of sensitive cells with ADR-microspheres results in 40% of cells containing hemoglobins as determined by benzidine staining at 87% growth inhibition. Similar treatment of ADR-resistant cells produces 24% of benzidine-positive cells at 72% growth inhibition. Furthermore, free and coupled forms of ADR stimulate heme synthesis 12- and 20-fold. Hemoglobin analysis of ADR-polymer induced cells demonstrates additional embryonic (Gower-2, X, Portland) and fetal (F) types of hemoglobin in comparison to uninduced cells which synthesize only small amounts of Gower-1 in sensitive cells and Gower-1 plus hemoglobin X in resistant cells. In addition, free and bound forms of Adriamycin differ markedly in the relative proportion of hemoglobin types that they induce. Free and coupled forms of ADR produce an increase in the {gamma}-globin mRNA synthesis in sensitive K-562 cells. These results demonstrate that both ADR-sensitive and -resistant K-562 cells can be induced to differentiate at the cell surface by ADR-microspheres and that this induction differs qualitatively from that of free ADR.

1 This work was supported by A. R. C. France (Association pour la Recherche sur le Cancer) and NATO Grant 86/314 for collaborative research.

2 To whom requests for reprints should be addressed.

Received 3/31/89. Revised 10/30/89. Accepted 11/13/89.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1990 by the American Association for Cancer Research.